Chloroquine

證據等級: L5

預測適應症: 4 個

Chloroquine: From Malaria to Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis

One-Sentence Summary

Chloroquine is a 4-aminoquinoline antimalarial and antirheumatic agent, classically used to treat malaria, adult rheumatoid arthritis, and systemic lupus erythematosus. The TxGNN model predicts it may be effective for Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis (RF+ pJIA), with 0 clinical trials and 2 publications currently supporting this specific direction.

Quick Overview

Item	Content
Original Indication	No India registration data available; known uses include malaria, adult RA, and SLE
Predicted New Indication	Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis
TxGNN Prediction Score	99.41%
Evidence Level	L5
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information, Chloroquine is a long-established DMARD (disease-modifying antirheumatic drug). Its immunomodulatory actions — including inhibition of lysosomal phospholipase A2, interference with Toll-like receptor signalling (TLR7/TLR9), suppression of MHC-II antigen presentation, and reduction of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) — form the mechanistic basis for its use in autoimmune conditions.

Rheumatoid factor-positive polyarticular JIA (RF+ pJIA) is the paediatric subtype most closely resembling adult seropositive rheumatoid arthritis, sharing autoantibody-driven synovitis and similar cytokine-mediated joint destruction pathways. Because the inflammatory drivers are mechanistically analogous to adult RA — a condition for which Chloroquine and its analogue hydroxychloroquine are recognised DMARDs — the TxGNN prediction carries biological plausibility.

However, no dedicated clinical trial data exists for Chloroquine specifically in RF+ pJIA. Historical literature in broader juvenile chronic arthritis populations (where Chloroquine was used as a second-line DMARD in the 1970s–1990s) provides only indirect, bridging support. Clinical validation specific to the RF+ polyarticular subtype remains absent.

Clinical Trial Evidence

Currently no related clinical trials registered for rheumatoid factor-positive polyarticular juvenile idiopathic arthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24334641	2014	Prospective Observational	The Journal of Rheumatology	Long-term real-world experience with leflunomide in JIA; provides DMARD management context but is not specific to Chloroquine
8627446	1996	Case Report	The Journal of Pediatrics	Two RF+ polyarticular JRA patients developed accelerated nodulosis on methotrexate; hydroxychloroquine addition arrested nodule progression in one — indirect evidence of antimalarial benefit in this specific subtype

India Market Information

Chloroquine is currently not registered in India. There are no active drug licenses on record (total registrations: 0).

Safety Considerations

Drug Interactions (467 total interactions identified; key examples listed below):

Major interactions — require clinical review before use:

Interacting Drug	Level	Clinical Concern
Agalsidase beta	Major	May reduce enzyme replacement therapy efficacy
Bupropion	Major	May lower seizure threshold
Cisapride	Major	Additive QT interval prolongation risk
Clarithromycin	Major	Additive QT interval prolongation risk
Dolasetron	Major	Additive QT interval prolongation risk
Granisetron	Major	Additive QT interval prolongation risk

Notable moderate interactions:

Interacting Drug	Level	Clinical Concern
Famotidine, Cimetidine	Moderate	May alter Chloroquine absorption or metabolism
Aluminum hydroxide, Calcium carbonate, Attapulgite	Moderate	Antacids may reduce Chloroquine gastrointestinal absorption
Glimepiride, Glipizide, Glyburide, Chlorpropamide, Acetohexamide, Insulin human	Moderate	Chloroquine may potentiate hypoglycaemic effects
Metronidazole, Loperamide, Aprepitant	Moderate	Variable pharmacokinetic or pharmacodynamic interactions

Please refer to the package insert for full safety information including key warnings and contraindications (CDSCO label data not yet available in this Evidence Pack).

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN model assigns a high prediction score (99.41%) and the biological mechanism is plausible — given RF+ pJIA shares key inflammatory pathways with adult seropositive RA — there are zero dedicated clinical trials and only 2 indirect literature references for this specific indication, yielding an evidence level of L5. This is insufficient to support clinical or regulatory advancement at this stage.

To proceed, the following is needed:

Retrieve formal MOA documentation (DrugBank API query to address DG002)
Obtain India CDSCO label / package insert to extract key warnings and contraindications (DG001 — currently Blocking severity)
Conduct a systematic review bridging hydroxychloroquine evidence in JIA subtypes to assess whether hydroxychloroquine data can support a Chloroquine indication
Evaluate feasibility of a Phase 2 proof-of-concept trial specifically in RF+ pJIA patients
Clarify regulatory pathway for India market entry if evidence strengthens
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.